Dose-Ranging Study in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Novartis

Status and phase: Completed; Phase 2

Conditions: COPD

Treatments: Drug: QAB149

Study type: Interventional

Funder types: Industry

Identifiers

NCT00098228

CQAB149B2205

Details and patient eligibility

About

The trial is designed to identify an appropriate dose of QAB149 for delivery via a multiple dose inhaler for use in the COPD Phase III program.

Enrollment: 686 patients

Sex: All

Ages: 40 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of COPD
• Age 40-75 years
• Smoking history

Exclusion criteria

• Other serious disease
• Allergy to QAB149
• Respiratory tract infection

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind